Media Centre
Latest press releases
-
Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma
-
The Lancet Respiratory Medicine publishes first Phase III trial for PT010 triple combination therapy in moderate to very severe chronic obstructive pulmonary disease
-
US FDA approves Lumoxiti (moxetumomab pasudotox-tdfk) for certain patients with relapsed or refractory hairy cell leukaemia
-
AstraZeneca to present Fasenra long-term safety and efficacy data at European Respiratory Society International Congress 2018
-
Tezepelumab granted Breakthrough Therapy Designation by US FDA
Medical Releases
These press releases are specifically for health specialist/medical media and are not for consumer press.
Contact us
Karen Birmingham
Director Global Science Media
Rob Skelding
Director Global Media Relations
Matthew Kent
Director Global Media Relations
Gonzalo Viña
Director Global Media Relations
Jacob Lund
Director External Communications, Sweden
Lotta Sjösten
Manager Media Relations, Sweden
US Media Team
